Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-Analysis, and cost effectiveness analysis

BMJ (Online)

Volumn 359, Issue , 2017, Pages

  López López, José A ^a   Sterne, Jonathan A C ^a,b   Thom, Howard H Z ^a   Higgins, Julian P T ^a,b   Hingorani, Aroon D ^c   Okoli, George N ^a   Davies, Philippa A ^a,d   Bodalia, Pritesh N ^e,f   Bryden, Peter A ^a   Welton, Nicky J ^a,b   Hollingworth, William ^a   Caldwell, Deborah M ^a   Savovic, Jelena ^a,d   Dias, Sofia ^a   Salisbury, Chris ^a   Eaton, Diane ^g   Stephens Boal, Annya ^h   Sofat, Reecha ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^g Anticoagulation Europe   (United Kingdom)

^h Thrombosis UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ALL CAUSE MORTALITY; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; MORTALITY RATE; PATIENT RISK; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; ORAL DRUG ADMINISTRATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG COSTS; HEMORRHAGE; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 85038011535     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j5058     Document Type: Review

References (42)

1. Kannel W, Wolf P, Benjamin E. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82(8A):2N-9N.
2. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. Royal College of Physicians, 2006.
3. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J Am Heart Assoc 2017;6:e005155. doi:10.1161/JAHA.116.005155
4. Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Clinical audit April-June 2015 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party. https://www. strokeaudit.org/Documents/National/PostAcuteOrg/2015/2015-PAOrgPublicReportPhase2.asp
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-Analysis. Ann Intern Med 1999;131:492-501. doi:10.7326/0003-4819-131-7-199910050-00003
6. Pirmohamed M, James S, Meakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9. doi:10.1136/bmj.329.7456.15
7. National Institute for Health and Clinical Excellence. Atrial fibrillation: The management of atrial fibrillation (CG180). London; 2014 https://www.nice.org.uk/guidance/cg180
8. Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: Time-Trend analysis from the General Practice Research Database. BMJ Open 2011;1:e000269. doi:10.1136/bmjopen-2011-000269
9. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 2015;386:303-10. doi:10.1016/S0140-6736(15)60245-8
10. Cope S, Clemens A, Hammes F, Noack H, Jansen JP. Critical appraisal of network meta-Analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. Value Health 2015;18:234-49. doi:10.1016/j.jval.2014.10.012
11. Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M. Mixed treatment comparison meta-Analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clin Ther 2013;35:967-984.e2. doi:10.1016/j. clinthera.2013.05.011
12. Dogliotti A, Paolasso E, Giugliano R. Current and new oral antithrombotics in non-valvular atrial fibrillation: A network metaanalysis of 79 808 patients. Heart 2014;5:396-405.doi:10.1136/heartjnl-2013-304347
13. Boehringer Ingelheim. A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with nonvalvular atrial fibrillation in comparison to warfarin NCT01136408. 2014. https://clinicaltrials.gov/ct2/show/NCT01136408
14. Yamashita T, Koretsune Y, Yasaka M. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012;76:1840-7. doi:10.1253/circj.CJ-11-1140
15. Hori M, Matsumoto M, Tanahashi N. J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-The J-ROCKET AF study-. Circ J 2012;76:2104-11. doi:10.1253/circj. CJ-12-0454
16. Centre for Reviews and Dissemination. Systematic Reviews: CRDs Guidance for Undertaking Reviews in Health Care. 3rd ed. University of York, Centre for Reviews and Dissemination, 2009.
17. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, 2008doi:10.1002/9780470712184.
18. Sterne JA, Bodalia PN, Bryden PA. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-Analysis and cost effectiveness analysis. Health Technol Assess 2017;21:1-386. doi:10.3310/hta21090
19. Higgins JPT, Altman DG, Gotzsche PC. Cochrane Bias Methods GroupCochrane Statistical Methods Group. The Cochrane Collaborations tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928
20. Connolly SJ, Eikelboom J, Joyner C. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. doi:10.1056/NEJMoa1007432
21. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-Analysis of randomized controlled trials. Med Decis Making 2013;33:607-17. doi:10.1177/0272989X12458724
22. Kansal AR, Sorensen SV, Gani R. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8. doi:10.1136/heartjnl-2011-300646
23. Hu DY, Zhang HP, Sun YH, Jiang LQ. Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:295-8.
24. Lopes RD, Alexander JH, Al-Khatib SM. ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9. doi:10.1016/j.ahj.2009.07.035
25. Eikelboom JW, ODonnell M, Yusuf S. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348-353.e1. doi:10.1016/j.ahj.2009.08.026
26. Ruff CT, Giugliano RP, Antman EM. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial
27. fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.e2. doi:10.1016/j.ahj.2010.06.042
28. Patel MR, Mahaffey KW, Garg J. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. doi:10.1056/NEJMoa1009638
29. Connolly SJ, Ezekowitz MD, Yusuf S. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. doi:10.1056/NEJMoa0905561
30. Chung N, Jeon HK, Lien LM. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011;105:535-44. doi:10.1160/TH10-07-0451
31. Weitz JI, Connolly SJ, Patel I. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104:633-41. doi:10.1160/TH10-01-0066
32. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation.-The ARISTOTLE-J study-. Circ J 2011;75:1852-9. doi:10.1253/circj.CJ-10-1183
33. Connolly SJ, Eikelboom J, Dorian P. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013;34:1498-505. doi:10.1093/eurheartj/eht039
34. Ezekowitz MD, Reilly PA, Nehmiz G. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26. doi:10.1016/j. Amjcard.2007.06.034
35. Lin L, Lim WS, Zhou HJ. Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. J Am Med Dir Assoc 2015;16:1103.e1-19. doi:10.1016/j. jamda.2015.09.008
36. Rasmussen LH, Larsen TB, Graungaard T, Skjoth F, Lip GYH. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012;345:e7097. doi:10.1136/bmj.e7097
37. Potpara TS, Lip GYH. Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. JAMA 2017;317:1115-6.
38. Healey JS, Oldgren J, Ezekowitz M. RE-LY Atrial Fibrillation Registry and Cohort Study Investigators. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: A cohort study. Lancet 2016;388:1161-9. doi:10.1016/S0140-6736(16)30968-0
39. Wells G, Coyle D, Cameron C. Safety, Effectiveness, and Cost effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. Therapeutic Review, 2012.
40. Huisman MV, Lip GYH, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47. doi:10.1160/TH11-10-0718
41. Cohen D. Manufacturer failed to disclose faulty device in rivaroxaban trial. BMJ 2016;354:i5131. doi:10.1136/bmj.i5131
42. Food and Drug Administration. FDA analyses conclude that Xarelto clinical trial results were not affected by faulty monitoring device 2016 [updated 10/11/2016]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm524678.htm.